FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number:	3235-0104						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address Posard Matthe	2. Date of Event Requ Statement (Month/Day 06/09/2021		3. Issuer Name and Ticker or Trading Symbol Nautilus Biotechnology, Inc. [ NAUT ]											
(Last) C/O NAUTILUS : 425 PONTIUS AV	(First) BIOTECHNOLOGY 'E N, STE 202	(Middle) , INC.			4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				5. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) SEATTLE (City)	WA (State)	98109 (Zip)			Officer (give title below)		Other (specify below)			Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person				
(3-9)	Table I - Non-Derivative Securities Beneficially Owned													
1. Title of Security (Instr. 4)				[2	2. Amount Owned (In	of Securities Beneficially str. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)					
Common Stock						100,000	I S			See Footnote <sup>(1)</sup>				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 4)		Expiration [	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underl Security (Instr. 4)		4. Conver	cise	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)				
		Date Exercisable	Expiration Date	Title		Amount or Number of Shares	r of Security		(instr. 5)					
Stock Option (Right to Buy)			(2)	02/28/2029		Common Stock	166,891	0.43		D				
Stock Option (Right to Buy)			(3)	10/15/2030	Common Stock		65,305	1.14		D				
Stock Option (Right to Buy)			(4)	01/31/2031		Common Stock	36,280	1	0	D				

#### Explanation of Responses:

- 1. Shares held by the Matthew and Elizabeth Posard Trust. The reporting person is the Trustee of the Matthew and Elizabeth Posard Trust.
- 2. Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidary, Inc. 2017 Equity Incentive Plan (the "Plan")) through each vesting date, one thirty-sixth (1/36th) of the shares subject to the Option shall vest monthly over the next thirty-six (36) months on the same day of the month as the Vesting Commencement Date (as defined below). Notwithstanding the foregoing, in the event of a Change in Control (as defined in the Plan) that occurs while the reporting person is a Service Provider, 100% of the total number of shares subject to the Option that have not yet vested shall immediately vest and be fully exercisable, effective as of immediately prior to the Change in Control (as defined in the Plan). The Vesting Commencement Date is February 1, 2019.
- 3. Subject to reporting person's continuous status as a "Service Provider" (as defined in the Plan) through each vesting date, one-forty eight (1/48th) of the shares subject to the Option shall vest monthly over the next forty-eight (48) months on the same day of the month as the Vesting Commencement Date (as defined below). Notwithstanding the foregoing and anything to the contrary in the Plan, in the event of a Change in Control (as defined in the Plan) of the Company, 100% of the total number of shares subject to the Option shall vest and become immediately exercisable; provided that reporting person's continuous status as a "Service Provider" (as defined in the Plan) has not been terminated prior to such time. The Vesting Commencement Date is September 1, 2020.

  4. Subject to reporting person's continuous status as a "Service Provider" (as defined in the Plan) has not been terminated prior to such time. The Vesting Commencement Date is September 1, 2020.

  4. Subject to reporting person's continuous status as a "Service Provider" (as defined in the Plan) has not been terminated prior to such time. The Vesting Commencement Date is September 1, 2020.

  4. Subject to reporting person's continuous status as a "Service Provider" (as defined in the Plan) has not been terminated prior to such time. The Vesting Commencement Date is September 1, 2020.

  4. Subject to reporting person's continuous status as a "Service Provider" (as defined in the Plan) has not been terminated prior to such time. The Vesting Commencement Date is September 1, 2020.

  4. Subject to reporting person's continuous status as a "Service Provider" (as defined in the Plan) has not been terminated prior to such time. The Vesting Commencement Date is September 1, 2020.

  5. Subject to reporting person's continuous status as a "Service Provider" (as defined below) and (b) the day immediately before the date of the next annual meeting of stockholders of the Company (or in the event of a merger or consolidation involving the Company in which the Company

# Remarks:

Exhibit 24: Power of Attorney

/s/ Anna Mowry, as Attorney-in-Fact

\*\* Signature of Reporting Person

06/09/2021

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Nautilus Biotechnology, Inc. (the "Company"), hereby constitutes and appoints Sujal Patel

1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion deto

2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national assoc.

The undersigned hereby ratifies and confirms all that said attorneys in-fact and agent shall do or cause to be done by virtue hereof. The undersigned hereby ratifies and confirms all that said attorneys in-fact and agent shall do or cause to be done by virtue hereof.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 9th day of June, 2021.

Signature: /s/ Matthew Posard
Print Name: Matthew Posard